班硝哗 | 31478-45-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 班硝哗
• 中文别名: 甲硝咪酯胺；班硝唑
• 英文名称: 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl carbamate
• 英文别名: bamnidazole；1-carbamoyloxy-2-(2-methyl-5-nitro-imidazol-1-yl)-ethane；2-(2-methyl-5-nitroimidazol-1-yl)ethyl carbamate
• CAS: 31478-45-2
• 化学式: C₇H₁₀N₄O₄
• 分子量: 214.181
• InChiKey: JOVXEDBYAWFQQX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  116
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  班硝哗 在 氯化亚砜 、 三乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 18.0h， 生成 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl N-(2,2,2-trichloro-1-((4,6-dichloropyrimidin-2-yl)amino)ethyl)carbamate
  参考文献：
  名称：

  Discovery of a Dual Tubulin Polymerization and Cell Division Cycle 20 Homologue Inhibitor via Structural Modification on Apcin

  摘要：

  Apcin is one of the few compounds that have been previously reported as a Cdc20 specific inhibitor, although Cdc20 is a very promising drug target. We reported here the design, synthesis, and biological evaluations of 2,2,2-trichloro-1-aryl carbamate derivatives as Cdc20 inhibitors. Among these derivatives, compound 9f was much more efficient than the positive compound apcin in inhibiting cancer cell growth, but it had approximately the same binding affinity with apcin in SPR assays. It is possible that another mechanism of action might exist. Further evidence demonstrated that compound 9f also inhibited tubulin polymerization, disorganized the microtubule network, and blocked the cell cycle at the M phase with changes in the expression of cyclins. Thus, it induced apoptosis through the activation of caspase-3 and PARP. In addition, compound 9f inhibited cell migration and invasion in a concentration-dependent manner. These results provide guidance for developing the current series as potential new anticancer therapeutics.

  DOI：

  10.1021/acs.jmedchem.9b02097
• 作为产物：
  描述：

  甲硝唑 在 ammonium hydroxide 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 班硝哗
  参考文献：
  名称：

  (1,1,1-三氯-2)氨基甲酸酯类衍生物及其制备方法和应用

  摘要：

  本发明涉及(1,1,1‑三氯‑2)氨基甲酸酯类衍生物，本发明还涉及它们的制备方法以及相关的医药用途。为实现上述目的，本发明提出一种(1,1,1‑三氯‑2)氨基甲酸酯类衍生物，结构通式如式(I‑III)所示：与现有技术相比，本发明的目标化合物的肿瘤抑制活性较apcin大为增强，在多个肿瘤细胞株中均显示出良好抑制作用；且有较好的微管聚集抑制作用，为寻找针对APC通路和微管抑制双功能癌症治疗方法开辟了新的途径。

  公开号：

  CN111606891B

文献信息

• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• 4-SUBSTITUTED 2-ARYLOXYPHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS
  申请人：Huang Liren

  公开号：US20070054884A1

  公开（公告）日：2007-03-08

  Antimicrobial compounds, compositions and methods of treatment administering same, of 2-aryloxyphenol derivatives having heterocyclic groups or highly polar functional groups substituted at position 4 of the phenolic ring, as well as methods for their preparation and formation, wherein the compounds are generally of Formula 1.

  抗菌化合物、组合物和治疗方法，涉及施用具有杂环基团或高极性官能团在酚环的4位上取代的2-芳氧基苯酚衍生物，以及它们的制备和形成方法，其中所述化合物通常具有式1的结构。
• Platinum(<scp>II</scp>) complexes of nitroimidazoles: synthesis, characterisation, and X-ray crystal structures of cis-dichlorobis[1-(2′-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole]platinum(<scp>II</scp>) and trans-dichlorobis[1-(2′-hydroxy-3′-methoxypropyl)-2-nitroimidazole]platinum(<scp>II</scp>)
  作者：John R. Bales、Muhammed A. Mazid、Peter J. Sadler、Aneel Aggarwal、Reiko Kuroda、Stephen Neidle、David W. Gilmour、Barry J. Peart、Christopher A. Ramsden

  DOI：10.1039/dt9850000795

  日期：——

  propyl)-2-nitroimidazole]platinum(II)[monoclinic crystals: a= 8.134(1), b= 13.014(1), c= 11.323(2)Å, β= 91.469(9)°, Z= 2, space group P21/a]. This complex showed an unusual loss of planarity between the nitro-group and the imidazole ring, giving a dihedral angle of 45.6°. The geometry of the 4-nitroimidazole complexes was not determined. Co-ordination of the nitroimidazole ligand to PtII lowered the

  已经通过包括195 Pt nmr光谱法在内的多种方法制备并表征了一系列[PtL 2 X 2 ]类型的配合物（其中L是取代的5-硝基咪唑，X 2是二卤化物或二羧酸盐）。这些5-硝基咪唑配合物具有顺式立体化学，例如通过X-射线晶体结构测定顺式-二氯双[1-（2'-羟乙基）-2-羟甲基-5-硝基咪唑]铂（II）[斜方晶体：a = 8.643（1），b = 24.052（3），c = 9.119（1）Å，Z = 4，空间组Pcan]。另外，制备了2-和4-硝基咪唑的许多类似的络合物。2-硝基咪唑似乎形成了热力学上有利的反式配合物，而不是动力学上有利的顺式产物。这证实了反-dichlorobis [1-（2'-羟基-3'-甲氧基丙基）-2-硝基咪唑]铂（II）[斜晶体：一个= 8.134（1），b = 13.014（1），C ^ = 11.323（2）Å，β= 91.469（9）°，Z = 2，空间群P
• [EN] DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF<br/>[FR] LIQUIDES IONIQUES À DOUBLE FONCTION ET SELS DE CEUX-CI
  申请人：UNIV ALABAMA

  公开号：WO2010078300A1

  公开（公告）日：2010-07-08

  Disclosed herein are ionic liquid compositions comprising active pharmaceutical, biological, and nutritional compounds, and methods of use. Further disclosed are compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are 'solvated,' for example, 'hydrated' and their uses.

  本文揭示了包括活性药物、生物学和营养化合物的离子液体组合物，以及其使用方法。进一步揭示了包括液态离子对的物质组合物，单独或溶解后使用；以及离子液体的“溶剂化”组合物，例如“水合”的组合物及其用途。
• Pharmaceutical preparation comprising an active dispersed on a matrix
  申请人：——

  公开号：US20040058896A1

  公开（公告）日：2004-03-25

  The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

  本发明涉及制药技术领域，描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。